• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 15.85
  • VXN 20.63
  • VXO 18.01
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
IMMU (Immunomedics Inc.)
Last Trade 14.8 Dividend/Share 0 PE Ratio -14.51
Date May 24-2019 Dividend Yield 0.000 Return on Assets -87.13
Change 0.37 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -1.75 Price/Sale 7,160.394
Ask null LatestEPS Date 2018-12-31 Price to Book 15.51
Volume null EPS ttm -1.020 Institutional % null
Avg Volume 2.7M Shares Outstanding 191.54M Insider % null
Open 14.52 Float 189.29M Short Ratio null
Prev Close 14.43 Return On Equity -290.72 5 Year Change % 3.253
High 14.83 Consensus EPS -0.28 2 Year Change % 0.917
Low 14.43 No. of Estimate 4.000 1 Year Change % -0.325
52 Week High 27.33 EPS Surprise $ null YTD Change % -0.012
52 Week Low 11.55 EPS Surprise Percent -25 6 Month Change % -0.173
52 Week Change -34.455 EBITDA 0M 3 Month Change % -0.089
50 Day MA 16.7426 Revenue 0M 1 Month Change % -0.103
200 Day MA Gross Profit 0M 5 Day Change % -0.041
Market Cap 2834.75M Cash 0M 30 Day Change % -0.200
Beta 2.037241 Debt 0M Stock Exchange NASDAQ Global Market
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Immunomedics, Inc. engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, and autoimmune and other serious diseases. Its products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin?s lymphoma; Veltuzumab, a Phase I/II clinical study product for the treatment of patients with non-Hodgkin?s lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkin?s lymphoma. The company?s preclinal trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug immunoconjugate therapy; and Labetuzumab, a product candidate that targets colon, rectum, breast, lung, and other solid tumors. In addition, the company markets and sells a diagnostic product, ?LeukoScan?, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. It also develops Dock-and-Lock method technology that combines conjugation chemistry and genetic engineering to enable the creation of novel human therapeutics, and the construction of enhanced recombinant products. The company distributes its products in the United States, Europe, and Japan. Immunomedics has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd. to develop vaccines against melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.